Zeta Factor XIIIa Antibody. Zeta’s recombinant mouse antibody recognizes Factor XIIIa, a fibrin stabilizing factor that is most commonly recognized as a marker of fibrohistiocytic proliferations but widely expressed in a variety of cell types. Factor XIIIa is derived from monocyte and macrophage myeloid lineage and expressed in dermal dendrocytes, primarily surrounding microvasculature in the adventitial dermis near the dermoepidermal junction and near skin appendages.
The Factor XIIIa antibody recognizes a protein of 83kDa. Factor XIIIa has been identified in platelets, megakaryocytes, and fibroblast-like mesenchymal or histiocytic cells in the placenta, uterus, and prostate, monocytes and macrophages and dermal dendritic cells. The Factor XIIIa antibody has been found to be useful in differentiating between dermatofibroma (almost all cases are positive), dermatofibrosarcoma protuberans (-/+) and desmoplastic malignant melanoma (-). The Factor XIIIa antibody positivity is also seen in capillary hemangioblastoma, hemangioendothelioma, hemangiopericytoma, xanthogranuloma, xanthoma, hepatocellular carcinoma, glomus tumor, and meningioma.
Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists. Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.